DI GIACOMO ANNA MARIA | Elenco docenti

Ascierto, P.a., Del Vecchio, M., Merelli, B., Gogas, H., Arance, A.m., Dalle, S., et al. (2026). Nivolumab for Resected Stage III or IV Melanoma at 9 Years. THE NEW ENGLAND JOURNAL OF MEDICINE [10.1056/NEJMoa2504966]. - dettaglio
Kennedy, O.J., Glassee, N., Kicinski, M., Buhrer, E., Valpione, S., Gandini, S., et al. (2025). Prognostic and predictive importance of body mass index and type 2 diabetes in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. EJC SKIN CANCER, 3 [10.1016/j.ejcskn.2025.100284]. - dettaglio
Buhrer, E., Glassee, N., Kicinski, M., Kennedy, O.J., Blank, C.U., Long, G.V., et al. (2025). Prognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab vs placebo in resected stage III melanoma. EJC SKIN CANCER, 3 [10.1016/j.ejcskn.2025.100727]. - dettaglio
Lofiego, M.F., Tufano, R., Bello, E., Solmonese, L., Marzani, F., Piazzini, F., et al. (2025). DNA methylation status classifies pleural mesothelioma cells according to their immune profile: implication for precision epigenetic therapy. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 44(1) [10.1186/s13046-025-03310-0]. - dettaglio
Solmonese, L., Lofiego, M.F., Fazio, C., Marzani, F., Piazzini, F., Bello, E., et al. (2025). The Immunomodulatory Activity of Thymosin Alpha 1 on Tumor Cell Lines and Distinct Immune Cell Subsets. ONCOTARGETS AND THERAPY, 18, 995-1012 [10.2147/OTT.S527785]. - dettaglio

Tutte le pubblicazioni